Arivihan
An online learning platform for Indian school students preparing for board curricula and competitive exams, with AI tutoring in vernacular languages.
₹958.6MSeries A
LeadA
Accel
Activity from announced rounds
Activity in this selectionOct 6, 2026 · AI · Sep 7, 2026
Accel invests in technology companies from seed and Series A through growth, with teams and investment activity in the US, Europe, Israel and India.
Alongside its early-stage and growth funds, Accel provides expansion capital to companies already in its portfolio and to new investments. The platform can therefore engage with a first institutional round, a bootstrapped business or a company financing broader scale.
Atoms is its pre-seed and seed platform for Indian and Indian-origin founders building anywhere. It combines capital with product, go-to-market and fundraising expertise; its current cohorts include Atoms AI and Atoms X.
- Rounds participated in
- 6
- Confirmed lead rounds
- 3 All roles disclosed
- New companies
- 5 First participation on record · 1 follow-on
- Funding in participating rounds
- $307M 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
6 in this selectionAndo
Ando provides team messaging where people and AI agents share conversations and working context.
$20MCombined pre-seed and seed
LeadEma
Ema builds AI Employees that automate multi-step work across enterprise HR, IT and finance systems. Businesses use its agents for processes such as recruiting, onboarding, benefits, IT support, invoice handling and payroll; the platform connects to existing applications and includes tools for configuring, governing and improving workflows.
$77MSeries B
ParticipantNuance Labs
Real-time audiovisual AI designed to see, hear, reason, speak and express itself in live conversation.
$50MSeries A
ParticipantCognition
Cognition develops Devin, an autonomous software-engineering system, and the Windsurf AI code editor.
>$2BSeries E
LeadForus
Connects healthcare providers, pharmacies, payers and biopharma through AI-assisted treatment-access workflows.
$150MSeries C
Participant